Full Text View
Tabular View
No Study Results Posted
Related Studies
Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
This study has been completed.
Study NCT00160407   Information provided by St. Louis University
First Received: September 8, 2005   Last Updated: November 19, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Fatty Liver
Hepatitis
Additional conditions recognized in this trial
Overweight
More general conditions related to this trial
Body Weight
Digestive System Diseases
Liver Diseases
Signs and Symptoms
Interventions listed in this trial
Orlistat (Xenical)
1400 kcal diet (30% fat)
Additional drug interventions recognized in this trial
Orlistat
More general drug interventions related to this trial
Anti-Obesity Agents
Central Nervous System Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
St. Louis University
Hoffmann-La Roche


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services